Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors

10. november 2026 oppdatert av: CStone Pharmaceuticals

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Detaljert beskrivelse

In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).

In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).

Studietype

Intervensjonell

Registrering (Antatt)

310

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • North Ryde, New South Wales, Australia, 2109
        • Macquarie University
        • Hovedetterforsker:
          • John Park, Dr
      • Randwick, New South Wales, Australia, 2031
        • Scientia Clinical Research Ltd
        • Hovedetterforsker:
          • Charlotte lemech, Dr
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Monash Medical Centre
        • Hovedetterforsker:
          • Sophia Frentzas, Dr
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200123
        • Shanghai East Hospital
        • Hovedetterforsker:
          • Caicun Zhou

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • Pathologically or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • Life expectancy ≥ 3 months.
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic immunosuppressive treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received live vaccine within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of hypersensitivity to excipients of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dose Escalation

Participants will be administered escalating doses of CS5006.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Eksperimentell: Dose Expansion

Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
[Doseutvidelse] Objektiv responsrate (ORR) evaluert av etterforskere i henhold til RECIST v1.1
Tidsramme: Opptil ca 2 år
Opptil ca 2 år
[Dose Escalation] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Tidsramme: Cycle 1 (Up to 21 Days)

Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

Cycle 1 (Up to 21 Days)
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Tidsramme: Up to approximately 2 years

The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

Up to approximately 2 years

Sekundære resultatmål

Resultatmål
Tidsramme
[Dose-eskalering] Objektiv responsrate (ORR) evaluert av etterforskere i henhold til RECIST v1.1
Tidsramme: Opptil ca 2 år
Opptil ca 2 år
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Expansion] The incidence and severity of adverse events (AEs)
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Tidsramme: Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Tidsramme: Up to approximately 2 years
Up to approximately 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. juli 2029

Studiet fullført (Antatt)

1. juli 2029

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CS5006-101

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere